ArticleCureus2025
Efficacy and Safety of Oral Cloxacillin Versus Amoxicillin-Clavulanic Acid in Treating Pediatric Acute Bacterial Lymphadenitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim and objectives Acute bacterial lymphadenitis is one of the most common causes of lymphadenopathy in children, whose treatment algorithm is not well defined in literature to date. The most commonly used drug for this condition is amoxicillin-clavulanic acid. However, given escalating antibiotic resistance, the use of narrower-spectrum agents like cloxacillin could be preferred. Thus, this study was planned to compare the safety and efficacy of oral cloxacillin and amoxicillin-clavulanic acid in pediatric bacterial lymphadenitis. Materials and methods This was a cohort analytical study done on children aged 1-14 years presenting with acute onset of lymphadenopathy. After establishing a bacterial etiology, the patients were randomized to receive either oral amoxicillin-clavulanic acid (Group A) or cloxacillin (Group B) and followed up as per protocol. The primary outcome was the duration of defervescence from the initiation of treatment. Secondary outcomes were a reduction in lymph node size, tenderness, leukocytosis, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Results A total of 192 patients were diagnosed with acute bacterial lymphadenitis and randomized into Group A (n = 99) and Group B (n = 93). Subjective and objective parameters obtained in both groups were compared before and after the initiation of treatment. The mean defervescence time for Group A was 5.92 days (95% confidence interval (CI): 5.15 to 6.69 days) and for Group B was 5.74 days (95% CI: 4.96 to 6.52 days). The upper bound of 95% CI in Group B (6.52) was only 0.5 days longer than the mean of Group A (5.92). This finding suggests the non-inferiority of cloxacillin in comparison with amoxicillin-clavulanic acid. Conclusion Oral cloxacillin is as effective and safe as compared to amoxicillin-clavulanic acid in uncomplicated pediatric bacterial lymphadenitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.